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How Much Is Enough?*Kristen K. Patton, MDSEE PAGE 524S udden cardiac death (SCD), arguably one ofthe most tragic causes of death, is estimatedto cause more than 300,000 fatalities annu-
ally in the United States (1). This complex underly-
ing pathophysiology usually requires interaction
between an abnormal substrate and a trigger lead-
ing to a sustained lethal ventricular arrhythmia
(2). Seminal primary prevention trials, SCD-HeFT
(Sudden Death in Heart Failure Trial) and MADIT-II
(Multicenter Automated Deﬁbrillator Implantation
Trial II), performed in patients determined to be at
high SCD risk on the basis of impaired left ventricu-
lar ejection fraction (LVEF) deﬁnitively demon-
strated the robust mortality beneﬁt afforded by
implantable cardioverter-deﬁbrillator (ICD) therapy
compared with medical care (3,4). However, a major
paradox is that despite focus on these high-risk
patients and the documented ability of ICDs to
save lives, most cardiac arrest events occur in the
unselected general population (5,6). In clinical life,
risk prediction is an uncertain science; prevention
is not straightforward, and guiding informed con-
versations with patients on this topic remains
challenging.
Current guidelines for primary prevention of SCD
rely on LVEF as the primary indication for an ICD on
the basis of epidemiologic evidence that LVEF is*Editorials published in the Journal of the American College of Cardiology
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mortality (7,8). Like many risk markers, LVEF is a
problematically nonspeciﬁc marker for mortality.
Because most victims of cardiac arrest have a rela-
tively normal LVEF, it is not, by itself, a sufﬁcient
marker for SCD risk (9,10). Additionally, despite
occurrence of SCD in those with even normal LVEF,
post-hoc analysis of secondary prevention trials sug-
gests a reduced ICD beneﬁt in individuals with higher
LVEF (11). Notably, the most marked ICD survival
beneﬁt has been seen in primary prevention trials
requiring additional markers of arrhythmic risk for
enrollment (12). Competing risks of death in the heart
failure (HF) population add additional complexity to
this calculus. Patients with severe HF, extremely low
LVEF, and poor functional status face such high risk
of pump failure death that even the most powerful
ICD cannot meaningfully extend life (13). Adding to
the puzzle is both the time- and measurement-
dependent variability of LVEF measurements in the
HF population (14,15).In this issue of the Journal, Zhang et al. (16) step
into this maelstrom to offer an important contribu-
tion to arrhythmic risk assessment in the HF popu-
lation. The authors evaluated the association
between changes in LVEF after primary prevention
ICD and biventricular-pacemaker ICD on ICD shocks
and mortality. Of 1,189 patients enrolled in the
PROSE-ICD (Prospective Observational Study of
Implantable Cardioverter-Deﬁbrillators), 538 patients
had their LVEF reassessed during follow-up; appro-
priate shock analysis was restricted to the 464
patients with LVEF reassessed before shock or those
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533who did not ever receive a shock. Subjects were
categorized into groups of worsened (LVEF decreased
>5%), improved (LVEF increased >5%), and no
change in LVEF, then separate analyses were per-
formed to evaluate the relationship with absolute
changes in LVEF.
Over an average 4.9 years of follow-up, 25% of the
538 patients improved LVEF to >35%, and 7%
improved to >55%; those who worsened were more
likely to be older, ischemic, and diabetic, and have
had a higher baseline LVEF. In the shock analysis, 27
individuals experienced a shock and, in adjusted Cox
models, the hazard ratio (HR) was substantially
decreased in the improved LVEF group (0.29; 95%
conﬁdence interval [CI]: 0.11 to 0.78). Among the 126
subjects whose LVEF improved to >35%, only 4 pa-
tients received a shock. Unsurprisingly, subjects
implanted with biventricular pacing devices were
more likely to experience LVEF improvement, but
device type did not change the association with out-
comes. The improved group experienced a similar
reduction in mortality risk; 96 patients died and the
HR for mortality was 0.33 (95% CI: 018 to 0.59).
These are small numbers, and the results of this
study should be interpreted with appropriate caution.
Patients who had LVEF reassessment were younger
and healthier. Four of 27 total shocks occurred in the
group whose LVEF improved to >35%, yet this was
15% of all appropriate shocks. These data are rela-
tively congruent with prior studies. In 91 consecutive
veterans undergoing generator replacement, 27% had
an LVEF improvement to >35%, yet 9 (36%) of these
patients versus 19 (29%) of patients with unchanged
LVEF experienced appropriate shocks and 3 of those 9
patients experienced their ﬁrst shock only after
generator replacement (17). In another cohort of 231
veterans, 26% no longer met primary prevention ICD
indications at generator replacement and those with
improved LVEF had a lower rate of ICD shocks (2.8%
vs. 10.7% annually) (18). Conversely, of 189 patients
enrolled in the DEFINITE (Deﬁbrillators in Non-
Ischemic Cardiomyopathy Treatment Evaluation)
trial who survived and had repeat LVEF measure-
ments, patients with improved LVEF had substan-
tially reduced mortality (HR: 0.09; 95% CI: 0.02 to0.39), but occurrence of appropriate shocks was not
related to LVEF improvement (19). We must bear in
mind that ICD programming differed in each of these
analyses, and this contributes substantially to shock
risk.
Given the inadequacy of LVEF for arrhythmic risk
assessment, we must look to other markers. A growing
body of literature has demonstrated the value of
delayed enhancement cardiac magnetic resonance in
deﬁning scar-based substrate that portends high
arrhythmic risk in numerous types of structural heart
disease (20,21). Importantly, signiﬁcant scarring
seems to deﬁne a relatively high arrhythmic risk
independent of LVEF, whereas lack of scar is associ-
ated with lower risk of ICD shocks. Unfortunately, ICD
lead coils and generator can produce too much artifact
to allow adequate visualization of percentage of
delayed enhancement in implanted patients.
Human brains are not well designed to confront
uncertainty. It is in this evolutionary and cultural
context that physicians are asked to help patients
decide if the beneﬁt of continued ICD therapy is worth
it, especially given the risks. For some, ICD therapy
results in gradual accumulation of complications; for
others, a life is saved. The perennial problem is
in identifying which patient might be in which cate-
gory. Zhang et al. (16) are to be congratulated for a
meticulous analysis and an important contribution in
a critical area of patient care. Their call for randomized
trials of generator replacement in this population
should be echoed. As a cautionary note, we know that
heart failure is a progressive disease. Over time, LVEF
may improve and then worsen again. If an ICD is not
replaced, the patient may be unprotected, with cata-
strophic results. Even in this largest series of
improved LVEF, there are but 134 subjects. Answering
the essential question will require longer-term
observational follow-up and integration with ran-
domized trial data, in considerably more patients.
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